Marcos Rothstein, MD
Nephrology · Saint Louis, MONPI 1285650507
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Baxter Healthcare at 35.4% of the total. Reporting peaked in 2019 at $189,673 and has fallen 82.0% since, to $34,118 in 2025. Among nephrology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 531 payments — averaging $659.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$124K
- Amgen$94K
- Fresenius USA Marketing, Inc.$54K
- Vantive US Healthcare LLC$32K
- Rockwell Medical, Inc.$22K
- Vifor Pharma, Inc.$13K
- plus $11K from 13 others
What the payments were for
- Consulting fees$129,70837%
- Speaking & faculty fees$159,28446%
- Travel & lodging$41,12512%
- Food & beverage$9,4913%
- Education$10,3783%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 152 | $123,966 |
| Amgen | 157 | $93,592 |
| Fresenius USA Marketing, Inc. | 92 | $53,957 |
| Vantive US Healthcare LLC | 60 | $32,114 |
| Rockwell Medical, Inc. | 11 | $21,856 |
| Vifor Pharma, Inc. | 26 | $13,341 |
| Daiichi Sankyo Inc. | 17 | $9,739 |
| Travere Therapeutics, Inc. | 3 | $369 |
| AstraZeneca | 2 | $250 |
| Cvrx, Inc. | 2 | $183 |
| Calliditas Therapeutics US Inc. | 1 | $128 |
| Bayer | 1 | $122 |
| OPKO Pharmaceuticals, LLC | 1 | $120 |
| Mallinckrodt Enterprises LLC | 1 | $77 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Novo Nordisk | 1 | $32 |
| Nxstage Medical, Inc. | 1 | $30 |
| Boston Scientific | 1 | $29 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - PD$123,130
- Parsabiv$89,391
- Velphoro$52,443
- TRIFERIC$21,810
- INJECTAFER$9,328
- Veltassa$6,690
- Renal - HD$5,176
- Renal - Acute$4,830
- Korsuva$3,911
- EPOGEN$2,000
- LOKELMA$129
- TARPEYO$128
- Filspari$125
- Kerendia$122
- FARXIGA$121
- Rayaldee$120
How this compares
$349,985 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 65 | $55,953 |
| EliquisApixaban | 43 | $29,869 |
| VeltassaPatiromer Calcium Sorbitex | 20 | $25,200 |
| JardianceEmpagliflozin | 15 | $12,887 |
| ProsolParenteral Amino Acid 20% No.1 | 57 | $6,738 |
| Repatha SyringeEvolocumab | 11 | $6,063 |
| Calcium Acetate | 51 | $3,391 |
| Sevelamer Carbonate | 34 | $3,048 |
| Midodrine Hcl | 28 | $2,090 |
| Calcitriol | 130 | $1,471 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $1,412 |
| Bumetanide | 27 | $893 |
| Irbesartan | 116 | $814 |
| Losartan Potassium | 106 | $710 |
| Mycophenolate Mofetil | 14 | $637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $250 | $55,95365 claims |
| Boehringer IngelheimJardiance | $19 | $12,88715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 nephrology providers in Missouri.
Other nephrology in Saint Louis
- Anuja JavaSaint Louis$240K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Krista LentineSaint Louis$86K
- Rowena Delos SantosSaint Louis$30K
- Kabeya MwintshiSaint Louis$25K
- Naoka MurakamiSaint Louis$24K
- Benjamin HumphreysSaint Louis$13K
- Leslie GewinSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.